Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CNCENASDAQ:INDVNASDAQ:IRONNASDAQ:KNSA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCNCEConcert Pharmaceuticals$8.37$8.37$2.66▼$8.55$401.26M0.522.97 million shsN/AINDVIndivior$13.89-0.3%$11.30$7.33▼$16.98$1.92B0.661.10 million shs555,885 shsIRONDisc Medicine$53.71+1.9%$45.86$30.82▼$68.73$1.86B0.73348,602 shs705,215 shsKNSAKiniksa Pharmaceuticals$28.30+2.1%$25.12$17.38▼$30.69$2.07B0.06516,217 shs907,293 shs7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCNCEConcert Pharmaceuticals0.00%0.00%0.00%0.00%0.00%INDVIndivior0.00%-1.28%+25.47%+43.49%-17.57%IRONDisc Medicine0.00%+7.38%+14.06%+5.27%+38.25%KNSAKiniksa Pharmaceuticals0.00%-6.38%+9.39%+25.17%+49.50%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCNCEConcert PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AINDVIndivior2.5666 of 5 stars1.65.00.00.03.41.71.9IRONDisc Medicine2.1548 of 5 stars3.52.00.00.02.22.50.0KNSAKiniksa Pharmaceuticals3.2302 of 5 stars3.53.00.00.02.93.30.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCNCEConcert Pharmaceuticals 0.00N/AN/AN/AINDVIndivior 3.25Buy$15.007.99% UpsideIRONDisc Medicine 3.09Buy$96.7080.04% UpsideKNSAKiniksa Pharmaceuticals 3.00Buy$38.8037.10% UpsideCurrent Analyst Ratings BreakdownLatest CNCE, IRON, INDV, and KNSA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/11/2025IRONDisc MedicineRaymond JamesSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageStrong-Buy$89.005/12/2025IRONDisc MedicineBMO Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$112.00 ➝ $120.004/29/2025KNSAKiniksa PharmaceuticalsJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$40.00 ➝ $45.004/16/2025KNSAKiniksa PharmaceuticalsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$34.00 ➝ $34.003/18/2025IRONDisc MedicineCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$99.00 ➝ $132.00(Data available from 6/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCNCEConcert Pharmaceuticals$32.58M12.32N/AN/A$3.24 per share2.58INDVIndivior$1.17B1.64$2.81 per share4.94N/A∞IRONDisc MedicineN/AN/AN/AN/A$14.17 per shareN/AKNSAKiniksa Pharmaceuticals$481.17M4.29N/AN/A$6.23 per share4.54Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCNCEConcert Pharmaceuticals-$80.05M-$3.21N/AN/AN/AN/A-109.43%-76.65%N/AINDVIndivior$2M-$0.31N/A8.12N/A-3.96%-241.73%15.09%7/24/2025 (Estimated)IRONDisc Medicine-$76.43M-$3.92N/AN/AN/AN/A-25.24%-23.96%8/6/2025 (Estimated)KNSAKiniksa Pharmaceuticals$14.08M-$0.25N/A113.20N/A-2.36%-7.31%-5.95%7/22/2025 (Estimated)Latest CNCE, IRON, INDV, and KNSA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2025Q1 2025IRONDisc Medicine-$0.99-$1.02-$0.03-$1.02N/AN/A4/29/2025Q1 2025KNSAKiniksa Pharmaceuticals$0.02$0.11+$0.09$0.11$128.35 million$137.79 million4/24/2025Q1 2025INDVIndivior$0.22$0.41+$0.19$0.38$240.13 million$266.00 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCNCEConcert PharmaceuticalsN/AN/AN/AN/AN/AINDVIndiviorN/AN/AN/AN/AN/AIRONDisc MedicineN/AN/AN/AN/AN/AKNSAKiniksa PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCNCEConcert PharmaceuticalsN/A9.039.03INDVIndiviorN/A0.830.65IRONDisc MedicineN/A19.3619.36KNSAKiniksa PharmaceuticalsN/A3.242.95Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCNCEConcert Pharmaceuticals70.63%INDVIndivior60.33%IRONDisc Medicine83.70%KNSAKiniksa Pharmaceuticals53.95%Insider OwnershipCompanyInsider OwnershipCNCEConcert Pharmaceuticals11.33%INDVIndiviorN/AIRONDisc Medicine4.24%KNSAKiniksa Pharmaceuticals53.48%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCNCEConcert Pharmaceuticals6447.94 million42.51 millionOptionableINDVIndivior1,164137.88 millionN/ANot OptionableIRONDisc Medicine3034.63 million28.50 millionNot OptionableKNSAKiniksa Pharmaceuticals22072.97 million32.80 millionOptionableCNCE, IRON, INDV, and KNSA HeadlinesRecent News About These CompaniesKiniksa Pharmaceuticals (NASDAQ:KNSA) Upgraded by Wall Street Zen to "Buy" RatingJune 15 at 3:51 AM | americanbankingnews.comKiniksa Pharmaceuticals (NASDAQ:KNSA) Upgraded at Wall Street ZenJune 14 at 1:57 AM | marketbeat.comKiniksa Pharmaceuticals (NASDAQ:KNSA) Stock Price Down 5.4% After Insider SellingJune 14 at 1:33 AM | americanbankingnews.comKiniksa Pharmaceuticals (NASDAQ:KNSA) Shares Down 5.4% on Insider SellingJune 12 at 1:42 PM | marketbeat.comBarry D. Quart Sells 6,900 Shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) StockJune 12 at 8:51 AM | insidertrades.comBarry D. Quart Sells 6,900 Shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) StockJune 11, 2025 | marketbeat.comBarry D. Quart Sells 8,212 Shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) StockJune 11, 2025 | marketbeat.comEben Tessari Sells 10,319 Shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) StockJune 11, 2025 | marketbeat.comKiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Director Barry D. Quart Sells 12,336 SharesJune 11, 2025 | marketbeat.comInsider Selling: Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) COO Sells 15,506 Shares of StockJune 11, 2025 | marketbeat.comKiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) COO Sells $1,374,231.42 in StockJune 11, 2025 | marketbeat.comUBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Purchases 12,462 Shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)June 10, 2025 | marketbeat.comAnalysts Set Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Price Target at $38.80June 10, 2025 | americanbankingnews.comKiniksa Pharmaceuticals (NASDAQ:KNSA) Reaches New 1-Year High - What's Next?June 9, 2025 | marketbeat.comKiniksa Pharmaceuticals (NASDAQ:KNSA) Cut to "Hold" at Wall Street ZenJune 9, 2025 | americanbankingnews.comKiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Stock Position Raised by Wellington Management Group LLPJune 7, 2025 | marketbeat.comKiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Given Average Rating of "Buy" by AnalystsJune 7, 2025 | marketbeat.comKiniksa Pharmaceuticals (NASDAQ:KNSA) Stock Rating Lowered by Wall Street ZenJune 7, 2025 | marketbeat.comKiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) CAO Sells $437,316.25 in StockJune 6, 2025 | insidertrades.comInsider Selling: Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) CAO Sells 15,211 Shares of StockJune 5, 2025 | marketbeat.comInsider Selling: Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) CFO Sells 18,299 Shares of StockJune 5, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCNCE, IRON, INDV, and KNSA Company DescriptionsConcert Pharmaceuticals NASDAQ:CNCEConcert Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which discovers and develops novel small molecule drugs through the use of deuterium technology. Its product candidates target a range of diseases including autoimmune disorders, inflammation, and central nervous system disorders. The company was founded by Richard H. Aldrich, Roger D. Tung and Christoph H. Westphal on April 12, 2006 and is headquartered in Lexington, MA.Indivior NASDAQ:INDV$13.89 -0.04 (-0.29%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$13.88 -0.01 (-0.04%) As of 06/13/2025 04:35 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose. Its core marketed products include SUBLOCADE and SUBUTEX PRO buprenorphine extended-release monthly injections; SUBOXONE, a buprenorphine and naloxone sublingual film; SUBOXONE, a buprenorphine and naloxone sublingual tablet; and SUBUTEX, a buprenorphine sublingual tablet for the treatment of opioid use disorder. The company also offers OPVEE nasal spray for opioid overdose reversal; and PERSERIS extended-release injectable suspension for the treatment of schizophrenia in adults. In addition, it is developing INDV-2000, a selective orexin-1 receptor antagonist that completed phase 1 clinical trial for the treatment of opioid use disorder (OUD); INDV-1000, a selective GABAb positive allosteric modulator, which is in pre-clinical development phase for the treatment of alcohol use disorder in collaboration with ADDEX therapeutics; INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc.; and CT-102, a digital therapeutic for the treatment of OUD in collaboration with Click Therapeutics. Further, the company is developing INDV-5004, a drinabant injection to treat acute cannabinoid overdose. It has a strategic partnership with Aelis Farma to develop AEF0117, a synthetic CB1 specific signaling inhibitor that is in phase 2B clinical trial for the treatment of cannabis use disorder. The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.Disc Medicine NASDAQ:IRON$53.71 +1.00 (+1.90%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$55.65 +1.94 (+3.61%) As of 06/13/2025 05:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Disc Medicine, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for the treatment of erythropoietic porphyrias, including erythropoietic protoporphyria, X-linked protoporphyria, and diamond-blackfan anemia; DISC-0974 for the treatment of anemia of myelofibrosis, and anemia of chronic kidney disease; and DISC-3405 for the treatment of polycythemia vera, and other hematologic disorders. The company's preclinical programs include DISC-0998, for the treatment of anemia associated with inflammatory diseases. Disc Medicine, Inc. was founded in 2017 and is headquartered in Watertown, Massachusetts.Kiniksa Pharmaceuticals NASDAQ:KNSA$28.30 +0.57 (+2.06%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$27.58 -0.72 (-2.56%) As of 06/13/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. The company was incorporated in 2015 and is based in Hamilton, Bermuda. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/09 - 06/13 Alphabet Enters a Bull Market: Is It Time to Buy? Ouster Soars 27% as DoD Grants First 3D LiDAR Approval for Drones RH Stock Rockets on Surprise Profit and Tariff Shift Super Micro Computer Stock: 2 Levels Smart Money Is Watching Intel's Price Spikes: Noise, or the First Notes of a Turnaround? IBM Up 10 Days in a Row: What’s Driving the Winning Streak? SoFi Stock’s Next Test: Can It Justify Its Premium Valuation? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
